Navigation Links
bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation

SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, has introduced a new product line of high medical value biomarkers for response, resistance and pathway interrogation called PRECIS Precision Medicine by bioTheranostics(SM). Precision medicine, a new paradigm in cancer management, partners accurate diagnosis of primary tumor site and predictive biomarkers to drive targeted therapy.  The PRECIS tests help oncologists predict potential response and evaluate underlying disease pathways as they consider targeted therapies.

The PRECIS product line includes biomarker profiles for non-small cell lung cancer and colorectal cancer and detects clinically relevant tumor biomarkers EGFR, ALK rearrangement, KRAS, BRAF, c-MET, PIK3CA and 10q23 deletion to aid in characterizing disease behavior and therapeutic effectiveness.

"An unmet need for targeted therapy treatments in metastatic cancer is accurate tumor classification plus knowledge of the activated signal transduction pathway driving cancer growth," said Richard Ding, Chief Executive Officer of bioTheranostics.  "The use of CancerTYPE ID®, the leading molecular classifier to aid physicians in ascertaining tumor origin, and PRECIS Precision Medicine biomarkers has significant potential to improve cancer diagnosis and help oncologists efficiently formulate an optimal personalized treatment plan.

"The launch of PRECIS is a key milestone for bioTheranostics as the company moves to become an integrated diagnostic solution provider in cancer management," said Ding.  "The PRECIS test menu provides cutting-edge tumor pathway information on therapeutic prediction and resistance mechanisms.

"We will continue to expand our testing menu as more predictive biomarkers demonstrate their clinical utility.  Our physician customers have also indicated that the turnaround time for the test results was important in their clinical decisions.  Our lab will respond to our client's needs by providing PRECIS test results within 7 to 10 days," Ding concluded.

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: breastcancerindex, which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; CancerTYPE ID, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin and PRECIS Precision Medicine by bioTheranostics, which includes clinically relevant oncology biomarkers for comprehensive cancer management.

For more information, call 1-858-587-5870 or visit

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2011, revenues reached euro 1.427 billion with 87% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at


Tim Schofield
Tel: + 1 858 587 5890

Koren Wolman-Tardy
Tel: + 011 33 6 13 94 51 14

SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. bioTheranostics Breast Cancer Index(SM) Predicts Risk for Late Recurrence in Early Stage ER-Positive Breast Cancer Patients
2. Upsher-Smith Launches B-Nexa® Prescription Prenatal Vitamin With B Vitamins and Ginger for Nausea and Vomiting of Pregnancy
3. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform:
4. iHealth Lab Launches Personalized Web Portal to Store Your Vitals
5. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
6. Neogen Launches Fully Quantitative Lateral Flow Test for DON
7. Ambry Genetics Launches Illumina MiSeq Next-Gen Sequencing Services
8. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
11. Life Technologies Launches 3500 Dx Series Genetic Analyzers for In Vitro Diagnostic Use in China
Post Your Comments:
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/25/2015)... November 25, 2015 2 nouvelles études ... les différences entre les souches bactériennes retrouvées dans ... des êtres humains . Ces recherches  ouvrent une ... la prise en charge efficace de l,un des ... les chats .    --> 2 nouvelles ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing ... AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf Association ... 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section Award ... work with turfgrass. , Clarke, of Iselin, N.J., is an extension specialist ...
Breaking Biology Technology:
(Date:11/18/2015)...  As new scientific discoveries deepen our understanding of ... providers face challenges in better using that knowledge to ... as more children continue to survive pediatric cancer, that ... age. John M. Maris, M.D ., a ... (CHOP) . --> John M. Maris, ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):